Molecular genetics of ependymoma

Chinese Journal of Cancer

Volumn 30, Issue 10, 2011, Pages 669-681

  Yao, Yuan ^a,b   Mack, Stephen C ^a,b   Taylor, Michael D ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brain tumor; Cells of origin; Cytogenetics; Ependymoma; Epigenetics; Gene expression; Genetics; Radial glial cells; Subgroups

Indexed keywords

LAMININ;

AMD1 GENE; APC GENE; ARHGEF5 GENE; BLU GENE; C22ORF2 GENE; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CASP8 GENE; CBX7 GENE; CDK11 GENE; CDKN2A GENE; CHI3L1 GENE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DAPK GENE; DBC1 GENE; DEC1 GENE; DOWN REGULATION; DUSP12 GENE; EGFR GENE; EPENDYMOMA; EPIGENETICS; FAMILIAL CANCER; FBX7 GENE; FHIT GENE; FN1 GENE; GAC1 GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE LOCUS; GENE LOSS; GENE MUTATION; GENETIC GAIN; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GLIA CELL; GSTP1 GENE; HDAC9 GENE; HIC 1 GENE; HOXA7 GENE; HOXA9 GENE; HSPA6 GENE; HTERT GENE; HUMAN; JAG1 GENE; JAGGED 1 2 GENE; JTB GENE; MCJ GENE; MEN1 GENE; MGMT GENE; MOLECULAR GENETICS; NF2 GENE; NOTCH1 GENE; NOTCH4 GENE; ONCOGENE; PRELP GENE; PROMOTER REGION; RAC2 GENE; RARB GENE; RASSF1A GENE; REVIEW; S100A10 GENE; SASH1 GENE; SBF1 GENE; SCHIP 1 GENE; SHC1 GENE; SIGNAL TRANSDUCTION; SNX9 GENE; SYNJ2 GENE; TFRSF10C GENE; TFRSF10D GENE; THBS1 GENE; TIMP3 GENE; TNFRSF10C GENE; TP53 GENE; TP63 GENE; TP73 GENE; TPR GENE; TUMOR SUPPRESSOR GENE; TWIST1 GENE; VEGF GENE; WNT5A GENE; ZIC1 GENE;

ADULT; ANIMALS; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; EPENDYMOMA; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; HUMANS; NEUROGLIA;

EID: 80054762055     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10129     Document Type: Review

References (118)

1. Bleyer WA. Epidemiologic impact of children with brain tumors [J]. Childs Nerv Syst, 1999,15(11-12):758-763.
2. Baldwin RT, Preston-Martin S. Epidemiology of brain tumors in childhood-a review [J]. Toxicol Appl Pharmacol, 2004,199 (2): 118-131.
3. Hasselblatt M. Ependymal tumors[J]. Recent Results Cancer Res, 2009,171:51-66.
4. Kilday JP, Rahman R, Dyer S, et al. Pediatric ependymoma: biological perspectives[J]. Mol Cancer Res, 2009,7(6):765-786.
5. Hadjipanayis CG, Van Meir EG. Brain cancer propagating cells: biology, genetics and targeted therapies [J]. Trends Mol Med, 2009,15(11):519-530.
6. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma [J]. Cancer Cell, 2005,8 (4):323-335.
7. Gilbert MR, Ruda R, Soffietti R. Ependymomas in adults [J]. Curr Neurol Neurosci Rep, 2010,10(3):240-247.
8. Kawabata Y, Takahashi JA, Arakawa Y, et al. Long-te rm outcome in patients harboring intracranial ependymoma [J]. J Neurosurg, 2005,103(1):31-37.
9. Merchant TE, Fouladi M. Ependymoma: new therapeutic approaches including radiation and chemotherapy[J]. J Neurooncol, 2005,75(3):287-299.
10. Kano H, Yang HC, Kondziolka D, et al. Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas [J]. J Neurosurg Pediatr, 2010,6(5):417-423.
11. van Veelen-Vincent ML, Pierre-Kahn A, Kalifa C, et al. Ependymoma in childhood: prognostic factors, extent of surgery, and adjuvant therapy [J]. J Neurosurg, 2002,97(4): 827-835.
12. Chamberlain MC. Ependymomas[J]. Curr Neurol Neurosci Rep, 2003,3(3):193-199.
13. Pollack IF. Brain-tu mors in children[J]. N Engl J Med, 1994,331(22):1500-1507.
14. Hamilton RL, Pollack IF. The molecular biology of ependymomas [J]. Brain Pathol, 1997,7(2):807-822.
15. Bouffet E, Foreman N. Chemotherapy for intracranial ependymomas [J]. Childs Nerv Syst, 1999,15(10):563-570.
16. Souweidane MM, Bouffet E, Finlay J. The role of chemotherapy in newly diagnosed ependymoma of childhood[J]. Pediatr Neurosurg, 1998,28(5):273-278.
17. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the children's cancer group [J]. J Clin Oncol, 2005,23(30):7621-7631.
18. Brandes AA, Cavallo G, Reni M, et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo Di Neuro-C ncologia [J]. Cancer, 2005,104(1):143-148.
19. Merchant TE. Current management of childhood ependymoma [J]. Oncology(Williston Park), 2002,16 (5):629-642, 644; discussion 645-646, 648.
20. Mabbott DJ, Spiegler BJ, Greenberg ML, et al. Serial evaluation of academic and behavioral outcome after treatment with cranial radiation in childhood [J]. J Clin Oncol, 2005,23 (10):2256-2263.
21. Spiegler BJ, Bouffet E, Greenberg ML, et al. Change in neurocognitive functioning after treatment with cranial radiation in childhood [J]. J Clin Oncol, 2004,22(4):706-713.
22. Pollack IF. Brain tumors in children[J]. N Engl J Med, 1994,331(22):1500-1507.
23. Pfister S, Hartmann C, Korshunov A. Histology and molecular pathology of pediatric brain tumors [J]. J Child Neurol, 2009,24 (11):1375-1386.
24. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis) [J]. N Engl J Med, 1988,318(11):684-688.
25. Rubio MP, Correa KM, Ramesh V, et al. Analysis of the neurofibromatosis2 gene in human ependymomas and astrocytomas [J]. Cancer Res, 1994,54(1):45-47.
26. von Haken MS, White EC, Daneshvar-Shyesther L, et al. Molecular genetic analysis of chromosome arm 17p and chromosome arm 22q DNA sequences in sporadic pediatric ependymomas [J]. Genes Chromosomes Cancer, 1996,17(1): 37-44.
27. Buccoliero AM, Castiglione F, Degl'Innocenti DR, et al. Merlin expression in pediatric anaplastic ependymomas real time PCR study [J]. Fetal Pediatr Pathol, 2010,29(4):245-254.
28. Albright AL, Adelson PD, Pollack IF. Principles and practice of pediatric neurosurgery [M]. Second edition. New York: Thieme, 2008.
29. Mullins KJ, Rubio A, Myers SP, et al. Malignant ependymomas in a patient with turcot s syndrome: case report and management guidelines [J]. Surg Neurol, 1998,49(3):290-294.
30. Torres CF, Korones DN, Pilcher W. Multiple ependymomas in a patient with turcot's syndrome [J]. Med Pediatr Oncol, 1997,28 (1):59-61.
31. Al-Salameh A, Francois P, Giraud S, et al. Intracranial ependymoma associated with multiple endocrine neoplasia type 1 [J]. J Endocrinol Invest, 2010,33(5):353-356.
32. Giraud S, Choplin H, Teh BT, et al. A large multiple endocrine neoplasia type 1 family with clinical expression suggestive of anticipation [J]. J Clin Endocrinol Metab, 1997,82(10):3487-3492.
33. Urioste M, Martinez-Ramirez A, Cigudosa JC, et al. Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma [J]. Cancer Genet Cytogenet, 2002,138(2):107-110.
34. Yokota T, Tachizawa T, Fukino K, et al. A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor [J]. J Hum Genet, 2003,48(11):598-602.
35. Dimopoulos VG, Fountas KN, Robinson JS. Familial intracranial ependymomas. Report of three cases in a family and review of the literature [J]. Neurosurg Focus, 2006,20(1):E8.
36. Nijssen PC, Deprez RH, Tijssen CC, et al. Familial anaplastic ependymoma: evidence of loss of chromosome 22 in tumour cells [J]. J Neurol Neurosurg Psychiatry, 1994,57(10):1245-1248.
37. Bergsagel DJ, Finegold MJ, Butel JS, et al. DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood [J]. N Engl J Med, 1992,326(15):988-993.
38. Suzuki SO, Mizoguchi M, Iwaki T. Detection of SV40 T antigen genome in human gliomas [J]. Brain Tumor Pathol, 1997,14(2): 125-129.
39. Lednicky JA, Garcea RL, Bergsagel DJ, et al. Natural simian virus 40 strains are present in human choroid plexus and ependymoma tumors [J]. Virology, 1995,212(2):710-717.
40. Kirschstein RL, Gerber P. Ependymomas produced after intracerebral inoculation of SV40 into new-born hamsters [J]. Nature, 1962,195:299-300.
41. Rabson AS, O'Conor GT, Kirschstein RL, et al. Papillary ependymomas produced in Rattus(Mastomys) natalensis inoculated with vacuolating virus (SV40) [J]. J Natl Cancer Inst, 1962,29:765-787.
42. Reuther FJ, Lohler J, Herms J, et al. Low incidence of SV40-like sequences in ependymal tumours [J]. J Pathol, 2001,195 (5):580-585.
43. Engels EA, Sarkar C, Daniel RW, et al. Absence of simian virus 40 in human brain tumors from northern India [J]. Int J Cancer, 2002,101(4):348-352.
44. Shah KV. SV40 and human cancer: a review of recent data [J]. Int J Cancer, 2007,120(2):215-223.
45. Strickler HD, Rosenberg PS, Devesa SS, et al. Contamination of poliovirus vaccines with simian virus 40(1955 -1963) and subsequent cancer rates [J]. JAMA, 1998,279(4):292-295.
46. Engels EA. Cancer risk associated with receipt of vaccines contaminated with simian virus 40: epidemiologic research [J]. Expert Rev Vaccines, 2005,4(2):197-206.
47. Johnson RA, Wright KD, Poppleton H, et al. Cross-s pecies genomics matches driver mutations and cell compartments to model ependymoma [J]. Nature, 2010,466(7306):632-636.
48. Palm T, Figarella-Branger D, Chapon F, et al. Expression profiling of ependymomas unravels localization and tumor grade-s pecific tumorigenesis [J]. Cancer, 2009,115 (17):3955-3968.
49. Mack SC, Taylor MD. The genetic and epigenetic basis of ependymoma [J]. Childs Nerv Syst, 2009,25(10):1195-1201.
50. de Bont JM, Packer RJ, Michiels EM, et al. Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective[J]. Neuro Oncol, 2008,10(6):1040-1060.
51. Karakoula K, Suarez-Merino B, Ward S, et al. Real-ti me quantitative PCR analysis of pediatric ependymomas identifies novel candidate genes including TPR at 1q25 and CHIBBY at 22q12 -q13 [J]. Genes Chromosomes Cancer, 2008,47 (11): 1005-1022.
52. Aschero S, Vallero S, Morra I, et al. A complex karyotype including a t (2;11) in a paediatric ependymoma: case report and review of the literature [J]. J Neurooncol, 2010,99(1):141-146.
53. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation [J]. Br J Cancer, 2002,86(6):929-939.
54. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups [J]. Am J Pathol, 2002,161(6):2133-2141.
55. Kraus JA, de Millas W, Sorensen N, et al. Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from HSNF5/INI1[J]. Acta Neuropathol, 2001,102(1):69-74.
56. Michalowski MB, de Fraipont F, Michelland S, et al. Methylation of RASSF1A and TRAIL pathway-re lated genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma [J]. Cancer Genet Cytogenet, 2006,166(1): 74-81.
57. Tong CY, Zheng PP, Pang JC, et al. Identification of novel regions of allelic loss in ependymomas by high-re solution allelotyping with 384 microsatellite markers[J]. J Neurosurg, 2001,95(1):9-14.
58. Hulsebos TJ, Oskam NT, Bijleveld EH, et al. Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2 [J]. Br J Cancer, 1999,81(7):1150-1154.
59. Mazewski C, Soukup S, Ballard E, et al. Karyotype studies in 18 ependymomas with literature review of 107 cases [J]. Cancer Genet Cytogenet, 1999,113(1):1-8.
60. Ammerlaan AC, de Bustos C, Ararou A, et al. Localization of a putative low-penetrance ependymoma susceptibility locus to 22q11 using a chromosome 22 tiling-path genomic microarray [J]. Genes Chromosomes Cancer, 2005,43(4):329-338.
61. Huang B, Starostik P, Kuhl J, et al. Loss of heterozygosity on chromosome22 in human ependymomas[J].Acta Neuropathol, 2002,103(4):415-420.
62. Suarez-Merino B, Hubank M, Revesz T, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1 -q13.3 [J]. Neuro Oncol, 2005,7(1):20-31.
63. Gil J, Bernard D, Martinez D, et al. Polycomb CBX7 has a unifying role in cellular lifespan[J]. Nat Cell Biol, 2004,6 (1): 67-72.
64. Sherr CJ, McCormick F. The RB and p53 pathways in cancer [J]. Cancer Cell, 2002,2(2):103-112.
65. Kato H, Kato S, Kumabe T, et al. Functional evaluation of p53 and PTEN gene mutations in gliomas[J]. Clin Cancer Res, 2000,6(10):3937-3943.
66. Watanabe T, Yokoo H, Yokoo M, et al. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas [J]. J Neuropathol Exp Neurol, 2001,60(12):1181-1189.
67. Nozaki M, Tada M, Kobayashi H, et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression [J]. Neuro Oncol, 1999,1(2):124-137.
68. Rajaram V, Leuthardt EC, Singh PK, et al. 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases [J]. Mod Pathol, 2004,17(1):9-14.
69. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas [J]. Cancer Genet Cytogenet, 2003,144 (2): 134-142.
70. Alonso ME, Bello MJ, Gonzalez-Gomez P, et al. Aberrant CpG island methylation of multiple genes in ependymal tumors [J]. J Neurooncol, 2004,67(1-2):159-165.
71. Sato K, Schauble B, Kleihues P, et al. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors [J]. Int J Cancer, 1996,66(3):305-308.
72. Goutebroze L, Brault E, Muchardt C, et al. Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins [J]. Mol Cell Biol, 2000,20(5):1699-1712.
73. Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics [J]. J Clin Oncol, 2006,24(33):5223-5233.
74. Ward S, Harding B, Wilkins P, et al. Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma [J]. Genes Chromosomes Cancer, 2001,32(1):59-66.
75. Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults[J]. J Clin Oncol, 2010,28(19):3182-3190.
76. Rousseau A, Idbaih A, Ducray F, et al. Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade [J]. J Neurooncol, 2010,97(3):353-364.
77. Hirose Y, Aldape K, Bollen A, et al. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups [J]. Am J Pathol, 2001,158(3):1137-1143.
78. Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma[J]. Clin Cancer Res, 2006,12(7 Pt 1):2070-2079.
79. Zhang XM, Dormady SP, Chaung W, et al. mVH1, a dual-specificity phosphatase whose expression is cell cycle regulated [J]. Mamm Genome, 2000,11(12):1154-1156.
80. Sharda PR, Bonham CA, Mucaki EJ, et al. The dual-s pecificity phosphatase hYVH1 interacts with Hsp70 and prevents heat- shock-in duced cell death [J]. Biochem J, 2009,418 (2):391-401.
81. Almeida A, Zhu XX, Vogt N, et al. GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas [J]. Oncogene, 1998,16(23):2997-3002.
82. Rand V, Prebble E, Ridley L, et al. Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma [J]. Br J Cancer, 2008,99(7):1136-1143.
83. Huang B, Starostik P, Schraut H, et al. Human ependymomas reveal frequent deletions on chromosomes 6 and 9 [J]. Acta Neuropathol, 2003,106(4):357-362.
84. Schneider D, Monoranu CM, Huang B, et al. Pediatric supratentorial ependymomas show more frequent deletions on chromosome 9 than infratentorial ependymomas: a microsatellite analysis [J]. Cancer Genet Cytogenet, 2009,191 (2):90-96.
85. Monoranu CM, Huang B, Zangen IL, et al. Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas [J]. Cancer Genet Cytogenet, 2008,182(1):18-26.
86. Korshunov A, Golanov A, Timirgaz V. P14ARF protein (FL-1 32) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases [J]. Acta Neuropathol, 2001,102(3):271-277.
87. Nishiyama H, Hornigold N, Davies AM, et al. A sequence-ready 840-k b PAC contig spanning the candidate tumor suppressor locus DBC1 on human chromosome 9q32-q33 [J]. Genomics, 1999,59(3):335-338.
88. Beetz C, Brodoehl S, Patt S, et al. Low expression but infrequent genomic loss of the putative tumour suppressor DBCCR1 in astrocytoma [J]. Oncol Rep, 2005,13(2):335-340.
89. Yang L, Leung AC, Ko JM, et al. Tumor suppressive role of a 2.4 Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma [J]. Oncogene, 2005,24(4):697-705.
90. Kunimoto Y, Nakano S, Kataoka H, et al. Deleted in esophageal cancer 1 (DEC1) is down-re gulated and contributes to migration in head and neck squamous cell carcinoma cell lines [J]. ORL J Otorhinolaryngol Relat Spec, 2011,73(1):17-23.
91. Moolenaar WH. Bioactive lysophospholipids and their G protein-coupled receptors [J]. Exp Cell Res, 1999,253(1):230-238.
92. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-re gulating kinase(ASK) 1 [J]. EMBO J, 1998,17(9):2596-2606.
93. Chen X, Tang W, Liu S, et al. Thioredoxin-1 phosphorylated at T100 is needed for its anti-apoptotic activity in HepG2 cancer cells [J]. Life Sci, 2010,87(7-8):254-260.
94. Pezzolo A, Capra V, Raso A, et al. Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma [J]. Cancer Lett, 2008,261(2):235-243.
95. Magrassi L, Marziliano N, Inzani F, et al. EDG3 and SHC3 on chromosome 9q22 are co-amplified in human ependymomas [J]. Cancer Lett, 2010,290(1):36-42.
96. Puget S, Grill J, Valent A, et al. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas [J]. J Clin Oncol, 2009,27(11):1884-1892.
97. Milde T, Pfister S, Korshunov A, et al. Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma [J]. Genes Chromosomes Cancer, 2009,48(3):229-238.
98. Tabori U, Wong V, Ma J, et al. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma [J]. Br J Cancer, 2008,99(7):1129-1135.
99. Tabori U, Ma J, Carter M, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma [J]. J Clin Oncol, 2006,24 (10):1522-1528.
100. Ridley L, Rahman R, Brundler MA, et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma [J]. Neuro Oncol, 2008,10(5):675-689.
101. Wong VC, Morrison A, Tabori U, et al. Telomerase inhibition as a novel therapy for pediatric ependymoma[J]. Brain Pathol, 2010,20(4):780-786.
102. Waha A, Koch A, Hartmann W, et al. Analysis of HIC-1 methylation and transcription in human ependymomas [J]. Int J Cancer, 2004,110(4):542-549.
103. Hamilton DW, Lusher ME, Lindsey JC, et al. Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma [J]. Cancer Lett, 2005,227(1):75-81.
104. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor [J]. J Cell Sci, 2007,120(Pt 18):3163-3172.
105. Lindsey JC, Lusher ME, Strathdee G, et al. Epigenetic inactivation of MCJ(DNAJD1) in malignant paediatric brain tumours [J]. Int J Cancer, 2006,118(2):346-352.
106. Peyre M, Commo F, Dantas-Barbosa C, et al. Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis [J]. PLoS One, 2010,5(9):e12932.
107. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development [J]. Nat Rev Neurosci, 2006,7(2):93-102.
108. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease [J]. Clin Cancer Res, 2002,8(10):3054-3064.
109. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia [J]. Science, 2004,306(5694):269-271.
110. Bocchetta M, Miele L, Pass HI, et al. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells [J]. Oncogene, 2003,22(1):81-89.
111. Donson AM, Birks DK, Barton VN, et al. Immune gene and cell enrichment is associated with a good prognosis in ependymoma [J]. J Immunol, 2009,183(11):7428-7440.
112. Montanaro L, Trere D, Derenzini M. Nucleolus, ribosomes, and cancer [J]. Am J Pathol, 2008,173(2):301-310.
113. Gilbertson RJ. Brain tumors provide new clues to the source of cancer stem cells: does oncology recapitulate ontogeny? [J]. Cell Cycle, 2006,5(2):135-137.
114. Campbell K, Gotz M. Radial glia: multi-purpose cells for vertebrate brain development [J]. Trends Neurosci, 2002,25(5): 235-238.
115. Spassky N, Merkle FT, Flames N, et al. Adult ependymal cells are postmitotic and are derived from radial glial cells during embryogenesis [J]. J Neurosci, 2005,25(1):10-18.
116. Poppleton H, Gilbertson RJ. Stem cells of ependymoma [J]. Br J Cancer, 2007,96(1):6-10.
117. Barry D, McDermott K. Differentiation of radial glia from radial precursor cells and transformation into astrocytes in the developing rat spinal cord [J]. Glia, 2005,50(3):187-197.
118. Merkle FT, Tramontin AD, Garcia-Verdugo JM, et al. Radial glia give rise to adult neural stem cells in the subventricular zone[J]. Proc Nat Acad Sci U S A, 2004,101 (50):17528-17532.